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The currently available human vaccine for anthrax, derived from the culture supernatant of Bacillus
anthracis, contains the protective antigen (PA) and traces of the lethal and edema factors, which may contribute
to adverse side effects associated with this vaccine. Therefore, an effective expression system that can provide
a clean, safe, and efficacious vaccine is required. In an effort to produce anthrax vaccine in large quantities and
free of extraneous bacterial contaminants, PA was expressed in transgenic tobacco chloroplasts by inserting
the pagA gene into the chloroplast genome. Chloroplast integration of the pagA gene was confirmed by PCR and
Southern analysis. Mature leaves grown under continuous illumination contained PA as up to 14.2% of the
total soluble protein. Cytotoxicity measurements in macrophage lysis assays showed that chloroplast-derived
PA was equal in potency to PA produced in B. anthracis. Subcutaneous immunization of mice with partially
purified chloroplast-derived or B. anthracis-derived PA with adjuvant yielded immunoglobulin G titers up to
1:320,000, and both groups of mice survived (100%) challenge with lethal doses of toxin. An average yield of
about 150 mg of PA per plant should produce 360 million doses of a purified vaccine free of bacterial toxins
edema factor and lethal factor from 1 acre of land. Such high expression levels without using fermenters and
the immunoprotection offered by the chloroplast-derived PA should facilitate development of a cleaner and
safer anthrax vaccine at a lower production cost. These results demonstrate the immunogenic and immuno-
protective properties of plant-derived anthrax vaccine antigen.
Anthrax, a fatal bacterial infection, is caused by Bacillus
anthracis, a gram-positive spore-forming organism. It is a zoo-
notic disease transmitted from animals to humans. CDC lists
Bacillus anthracis as a category A biological agent due to its
severity of impact on human health, high mortality rate, acute-
ness of disease, and potential for delivery as a biological
weapon. The disease is acquired when spores enter the body
through the skin or by inhalation or ingestion. Virulent strains
of B. anthracis contain plasmids pX01, which carries genes
encoding the toxins, and pX02, which encodes the poly-D-
glutamic acid capsule. Plasmid pX01 carries the genes pagA,
lef, and cya that encode the protective antigen (PA), lethal
factor (LF), and edema factor (EF), respectively. The term
“protective antigen” is derived because of this protein’s ability
to elicit a protective immune response against anthrax. None
of these proteins is toxic when administered individually to
cells or animals. However, PA in combination with EF, known
as edema toxin, causes edema. Similarly, PA in combination
with LF forms lethal toxin (LT) (1, 5).
PA is the primary immunogen and key component of human
vaccines produced and licensed in the United Kingdom and
United States. The current U.S. vaccine (BioThrax; BioPort
Corp.) consists of an alum-absorbed, formalin-treated culture
supernatant of a toxigenic, nonencapsulated strain of B. an-
thracis. The British anthrax vaccine is produced from superna-
tant of a static culture of the Sterne strain, a nonencapsulated
toxigenic variant of B. anthracis, adsorbed to aluminum salts.
These vaccines contain predominantly PA, but also small
quantities of LF and trace amounts of EF (31). These traces of
LF and EF may contribute to the vaccine side effects, such as
local pain and edema (19), and relatively high rates of local and
systemic reactions, including inflammation, flu-like symptoms,
malaise, rash, arthralgia, and headache (14, 29). Therefore, an
effective expression system that can provide a clean, safe, and
efficacious vaccine is required.
Recombinant PA has been expressed in Escherichia coli
(15), Lactobacillus casei (32), and Salmonella enterica serovar
Typhimurium (6). Expression of PA in plants through chloro-
plast transformation has several advantages over bacterial and
mammalian expression systems. Foreign proteins have been
expressed at extraordinarily high levels in transgenic chloro-
plasts due to the presence of 10,000 copies of the chloroplast
genomes per cell. These include AT-rich proteins such as
Cry2a (67% AT) at 47% of the total soluble protein (TSP)
(11), cholera toxin B chain fusion protein (59% AT) at 33%
TSP (23), and human serum albumin (66% AT) up to 11.1%
TSP (12). Therefore, we first tested the feasibility of expressing
PA in transgenic chloroplasts (30), but no further studies were
possible because no tag was used in that study to facilitate
purification. In addition to high levels of transgene expression,
there are several other advantages to chloroplast genetic en-
gineering. Several genes can be introduced in a single trans-
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formation event to facilitate development of multivalent vac-
cines (11, 28). Gene silencing is a common concern in nuclear
transformation, but this has not been observed in transgenic
chloroplasts in spite of hyperexpression of transgenes (11).
There is minimal risk of animal or human pathogens contam-
inating the vaccine as seen with mammalian expression sys-
tems. Additionally, chloroplast expression systems minimize
cross-pollination of the transgene due to the maternal inheri-
tance of the chloroplast genome (8).
In this study, we expressed PA with a histidine tag in trans-
genic chloroplasts, characterized the resultant transgenic
plants, and performed immunization studies. We compared
the efficacy of the plant-derived PA with that of PA derived
from B. anthracis in both in vitro and in vivo studies.
MATERIALS AND METHODS
Construction of pLD-VK1 vector for chloroplast transformation. The six-
histidine tag and the factor Xa cleavage site with NdeI and XhoI restriction sites
were introduced N terminal to pagA using PCR (Fig. 1a). The PCR-amplified
region was sequenced and shown to match corresponding pagA database se-
quences (accession no. AY700758). The PCR product was then cloned into
pCR2.1 vector containing the psbA 5 untranslated region (UTR). Finally, the
fragment containing the 5 UTR, His tag, and pagA was cloned into tobacco
universal vector pLD-ctv to produce pLD-VK1 (Fig. 1a).
Leaf bombardment and selection protocol. Microprojectiles coated with plas-
mid DNA (pLD-VK1) were bombarded into Nicotiana tabacum var. petit Havana
leaves using the biolistic device PDS1000/He (Bio-Rad) as described elsewhere
(9). Following incubation at 24°C in the dark for 2 days, the leaves were cut into
small (5 mm by 5 mm) pieces and placed abaxial side up (five pieces/plate) on
selection medium (RMOP [regeneration medium of plants] containing 500 mg/
liter spectinomycin dihydrochloride [9]). Spectinomycin-resistant shoots ob-
tained after about 6 weeks were cut into small pieces (2 mm by 2 mm) and
placed on plates containing the same selection medium.
Confirmation of transgene integration into the chloroplast genome. To con-
firm the transgene cassette integration into the chloroplast genome, PCR was
performed using the primer pairs 3P (5-AAAACCCGTCCTCEGTTCGGATT
GC-3) and 3 M (5-CCGCGTTGTTTCATCAAG-CCTTACG-3) (10), and to
confirm the integration of gene of interest, PCR was performed using primer
pairs 5P (5-CTGTAGAAGTC-ACCATTGTTGTGC-3) and 2 M (5-TGACT
GCCCACCTGA-GAGCGGACA-3) (10).
Southern blot analysis. Two micrograms of plant DNA per sample (isolated
using DNeasy kit) digested with BglII was separated on a 0.7% (wt/vol) agarose
gel and transferred to a nylon membrane. The chloroplast vector DNA digested
with BglII and BamHI generated a 0.8-kb probe homologous to the flanking
sequences. Hybridization was performed using the Ready-To-Go protocol (Phar-
macia).
Immunoblot analysis. Transformed and untransformed leaves (100 mg) were
ground in liquid nitrogen and resuspended in 500 l of extraction buffer (200
mM Tris-HCl, pH 8.0, 100 mM NaCl, 10 mM EDTA, 2 mM phenylmethylsul-
fonyl fluoride). Leaf crude extracts, boiled (4 min) or unboiled, in sample buffer
(Bio-Rad) were subjected to sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE). Thirty percent acrylamide Bis solution (Bio-Rad) was
used to make the 10% gels. The gel was run in 1 electrode buffer (10
electrode buffer is 30.3 g Tris base, 144.0 g glycine, and 10.0 g SDS added to 1,000
ml distilled water). The separated proteins were then transferred to nitrocellu-
lose, and Western blot analyses was performed using anti-PA primary antibody
(Immunochemical labs) diluted in phosphate-buffered saline (PBS)–0.1%
Tween–3% milk powder (PTM) (1:20,000) and secondary horseradish peroxi-
dase (HRP)-conjugated goat anti-mouse immunoglobulin G (IgG) (Sigma) di-
luted in PTM (1:5,000) followed by washing with PBS and finally incubated with
Lumiphos WB (Pierce) as a substrate for HRP at room temperature for 5 min for
chemiluminescence.
ELISA for PA. Leaf samples (100 mg of young, mature, or old leaves) were
collected from plants exposed to regular (16 h of light and 8 h of dark) or
continuous illumination. The extraction buffer (15 mM Na2CO3, 35 mM
NaHCO3, 3 mM NaN3, pH 9.6, 0.1% Tween, 5 mM phenylmethylsulfonyl fluo-
ride) was used to isolate plant protein. All dilutions were made in the coating
buffer (15 mM Na2CO3, 35 mM NaHCO3, 3 mM NaN3, pH 9.6). Antibodies were
used at dilutions similar to those in the Western blotting protocol. Wells were
then loaded with 100 l of 3,3,5,5-tetramethylbenzidine (TMB; American Qua-
lex) substrate and incubated for 10 to 15 min at room temperature. The reaction
was terminated by adding 50 l of 2 N H2SO4 per well, and the plate was read
on a plate reader (Dynex Technologies) at 450 nm.
Purification of His-tagged PA by affinity chromatography. His affinity chro-
matography using nickel-chelate-charged columns (Amersham Biosciences) was
used to purify His-tagged PA as per the manufacturer’s protocol. The buffers
used for purification include the following: binding buffer, 20 mM Na2HPO4, 0.5
M NaCl, 10 mM imidazole, pH 7.4; elution buffer, 20 mM Na2HPO4, 0.5 M
NaCl, 0.5 M imidazole, pH 7.4; and Ni-loading eluent, 100 mM NiSO4 solution
(Sigma). Protein samples were analyzed for PA using enzyme-linked immunosor-
bent assay (ELISA). Eluate fractions containing purified PA were pooled to-
gether and dialyzed against PBS, pH 7.4, using dialysis cassettes (molecular
weight, 10,000; Pierce) and concentrated using Centricon 10,000-molecular-
weight-cutoff ultrafiltration units (Millipore) following the manufacturer’s pro-
tocols.
Macrophage lysis assay. Macrophage lysis assays were performed on the crude
leaf extracts, partially purified chloroplast-derived PA, and B. anthracis-derived
PA. RAW264.7 macrophage cells were plated in 96-well plates in 120 l Dul-
becco’s modified Eagle’s medium and grown to 50% confluence. The plant
samples or solutions containing 20 g/ml of the purified PA proteins were
diluted serially 3.14-fold in a separate 96-well plate and then transferred onto the
RAW264.7 cells in such a way that the top row had plant extract at a 1:50 dilution
and PA at 0.4 g/ml. Cells were incubated with LT for 2.5 h, and the cell viability
was assessed by addition of MTT [3-(4, 5-dimethylthiazo-2-yl)-2,5-diphenyltet-
razolium bromide] (Sigma, St. Louis, MO) at a final concentration of 0.5 mg/ml.
Cells were then further incubated with MTT for 40 min, and the blue pigment
produced by viable cells was dissolved by aspirating the medium and adding 50
l/well of a mixture containing 0.5% (wt/vol) SDS and 25 mM HCl in 90%
(vol/vol) isopropanol and shaking the plates for 5 min prior to reading at 570 nm
using a microplate reader. Control plates received medium with no LF to test
toxicity of plant material and buffers.
Immunization studies in mice. The immunization studies were conducted in
accordance with federal and institutional guidelines. Seven groups of five female
6- to 7-week-old BALB/c mice (Charles River) were immunized subcutaneously
(s.c.; 5 g PA) at two sites (100 l per site) on day 0. The groups include mice
immunized with (i) chloroplast-derived PA (CpPA) with adjuvant, (ii) chloro-
plast-derived PA (CpPA) alone, (iii) Std.PA derived from B. anthracis with
adjuvant, (iv) Std-PA alone (26), (v) PA plant leaf crude extract with adjuvant,
or (vi) wild-type plant leaf crude extract with adjuvant and (vii) unimmunized
mice. The measurement of PA adsorbed to alhydrogel was done as described
previously (20). Booster doses were administered on day 14, day 28, and day 140.
Blood was drawn from the retro-orbital plexus 15 days after the third and fourth
doses (i.e., on days 43 and 155 of post-initial immunization). The blood samples
were allowed to stay undisturbed for 2 h at room temperature, stored at 4°C
overnight, and centrifuged at 3,000 rpm for 10 min to extract the serum.
ELISA to detect the anti-PA IgG antibodies in the serum samples. Ninety-
six-well microtiter ELISA plates were coated with 100 l/well of PA standard at
a concentration of 2.0 g/ml in PBS, pH 7.4. The plates were stored overnight at
4°C. The serum samples from the mouse were serially diluted (1:100 to
1:640,000). Plates were incubated with 100 l of diluted serum samples for 1 h at
37°C followed by washing with PBS-Tween. The plates were then incubated for
1 h at 37°C with 100 l of HRP-conjugated goat anti-mouse IgG (1:5,000 dilution
of 1-mg/ml stock). TMB was used as the substrate, and the reaction was stopped
by adding 50 l of 2 M sulfuric acid. The plates were read on a plate reader
(Dynex Technologies) at 450 nm. Titer values were calculated using a cutoff
value equal to an absorbance difference of 0.5 between immunized and unim-
munized mice (25).
Toxin neutralization assays. Sera from immunized mice were tested for neu-
tralization in the macrophage cytotoxicity assay described above. LT (PA plus
LF) was added at 50 ng/ml in Dulbecco’s modified Eagle’s medium to 96-well
plates (100 l/well, except 150 l in first well). Serum from each mouse was
diluted directly into the LT plates starting at 1:150 and proceeding in 3.14-fold
dilutions. Each serum was tested in triplicate. Following a 30-min incubation of
sera with toxin, 90 l of the mixture was moved to a 96-well plate containing
RAW264.7 cells grown to 90% confluence and incubated for 5 h at 37°C. MTT
was then added (final concentration, 0.5 mg/ml), and cell death was assessed as
described above. Neutralization curves were plotted, and 50% effective concen-
trations (EC50s) were calculated for the averaged data from each mouse serum
using GraphPad Prism 4.0 software.
Toxin challenge in mice. Groups of five mice with various immunization
treatments described above were injected intraperitoneally with 150 g LT (150
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FIG. 1. Vector map and confirmation of transgene integration into chloroplast genome by PCR and Southern blotting. (a) Schematic
representation of pLD-VK1 vector with protective antigen gene (pagA), aadA (selectable marker), 5 UTR, and chloroplast flanking sequences for
site-specific integration with the primers 3P/3M and 5P/2M annealing sites within the native chloroplast genome and the schematic diagram of
expected products from digestion of plants transformed with pLD-VK1. (b) Schematic diagram of expected products from digestion of wild-type
untransformed plant. (c) Confirmation of site-specific transgene cassette integration by PCR using primers (3P/3M) to yield a 1.65-kb product.
Lane 1, 1-kb DNA ladder; lane 2, wild type; lanes 3 to 6, pLD-VK1 transgenic lines; lane 7, positive control (interferon
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g LF plus 150 g PA) in sterile PBS (1 ml). Mice were monitored every 8 h for
signs of malaise and mortality.
RESULTS AND DISCUSSION
Chloroplast vector design. The pLD-VK1 vector (Fig. 1a)
contains homologous sequences that facilitate recombination
of the pag gene cassette between the trnI and trnA genes of the
native chloroplast genome (9). The constitutive 16S rRNA
promoter regulates expression of the aadA (aminoglycoside 3
adenyltransferase) gene. The pagA gene is regulated by the
psbA promoter and 5 and 3 UTRs. The psbA 5 UTR has
several sequences for ribosomal binding that act as a scaffold
for the light-regulated proteins involved in ribosomal binding
to enhance translation (12), and the psbA 3 UTR serves to
stabilize the transcript.
Demonstration of transgene integration. Several shoots ap-
peared 5 to 6 weeks after the bombardment of tobacco leaves
with gold particles coated with the pLD-VK1 plasmid DNA
(Fig. 1a). There are three genetic events that can lead to
survival of shoots on the selective medium: chloroplast inte-
gration, nuclear integration, or spontaneous mutation of the
16S rRNA gene to confer resistance to spectinomycin in the
ribosome. True chloroplast transformants were distinguished
from nuclear transformants and spontaneous spectinomycin
resistance mutants by PCR. Previously described primers, 3P
and 3M, were used to test for chloroplast integration of trans-
genes (9). The 3P primer anneals to the native chloroplast
genome within the 16S rRNA gene. The 3M primer anneals to
the aadA gene (Fig. 1a). Nuclear transformants could be dis-
tinguished because 3P will not anneal and mutants were iden-
tified because 3M will not anneal. Thus, the 3P and 3M primers
will only yield a product (1.65 kb) from true chloroplast inte-
grants (Fig. 1c).
The integration of the transgenes was further tested by using
the 5P and 2M primer pairs for PCR analysis. The 5P and 2M
primers anneal to the internal region of the aadA gene and the
internal region of the trnA gene, respectively, as shown in Fig.
1a (9). The product size of a positive clone is 3.9 kb for PA,
while the mutants and the control do not show any product.
Figure 1d shows the result of the 5P/2M PCR analysis. After
PCR analysis using both primer pairs, the transgenic plants
were subsequently transferred through different rounds of se-
lection to obtain mature plants and reach homoplasmy.
Southern blot analysis of transgenic plants. The plants that
tested positive by PCR analysis were moved through three
rounds of selection and were then evaluated by Southern anal-
ysis. The flanking sequence probe (0.81 kb, Fig. 1b) allowed
detection of the site-specific integration of the gene cassette
into the chloroplast genome (9). Figure 1a shows the BglII
sites used for the restriction digestion of the chloroplast DNA
for pLD-VK1. The transformed chloroplast genome digested
with BglII produced fragments of 5.2 kb and 3.0 kb for pLD-
VK1 (Fig. 1e), while the untransformed chloroplast genome
that had been digested with BglII formed a 4.4-kb fragment.
The flanking sequence probe can also show if homoplasmy of
the chloroplast genome had been achieved through the three
rounds of selection. The plants expressing PA showed slight
degree of heteroplasmy in one or two transgenic lines, as few
of the wild-type genomes were not transformed. This is not
uncommon and could be eliminated by germinating seeds on
stringent selection medium containing 500 g/ml spectinomy-
cin. The gene-specific probe with a size of approximately 0.52
kb was used to show the specific gene integration producing a
3-kb fragment containing the pagA gene as shown in Fig. 1f.
Immunoblot detection of PA expression. To determine
whether the transgenic plants were producing PA, immunoblot
analysis was performed on leaf extracts. Probing blots with
anti-PA monoclonal antibody revealed full-length 83-kDa pro-
tein (Fig. 2a). PA has protease-sensitive sequences at residues
164 and 314 that are easily cleaved by trypsin and chymotryp-
sin, respectively, resulting in polypeptides of 63 kDa and 20
kDa (for trypsin) or 47 kDa and 37 kDa (for chymotrypsin).
FIG. 2. Immunoblotting analysis and quantification of PA ex-
pressed in chloroplast of transgenic plants (pLD-VK1) in T0 genera-
tion. (a) Immunoblotting demonstrating the expression of PA in trans-
genic plant crude extracts. Lane 1, wild type; lane 2, 100-ng standard;
lane 4, transgenic line 5; lane 6, transgenic line 7; lane 8, transgenic line
8; lanes 3, 5, and 7, empty. (b) Expression levels in percent TSP of
PA-expressing leaves (young, mature, and old) under normal and
continuous illumination observed for 0 to 7 days.
clone). (d) Confirmation of gene integration by PCR using primers (5P/2M) to yield a 3.9-kb product. Lane 1, 1-kb-plus DNA ladder; lane 2, wild
type; lanes 3 and 4, pLD-VK1 transgenic lines. (e) Southern blots with flanking sequence probe in pLD-VK1 transgenic lines showing the following:
lane 1, wild type; lane 2, transgenic line 1; lane 3, transgenic line 2; lane 4, transgenic line 3; lane 5, transgenic line 4. (f) Southern blotting with
PA gene-specific probe showing the presence of pagA in the transgenic plants. Lane 1, wild type; lanes 2, 3, and 4, pLD-VK1 transgenic lines.
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The absence of these or other such bands demonstrates that
PA is intact within the chloroplast (Fig. 2a). The supernatant
samples from wild-type plants did not show any band, indicat-
ing that anti-PA antibodies did not cross-react with any plant
proteins in the crude extract.
Quantification of PA using ELISA. The PA protein expres-
sion levels of pLD-VK1 plants of T0 generation reached up to
4.5% of TSP in mature leaves under normal illumination con-
ditions (16 h of light and 8 h of dark, Fig. 2b). The psbA
regulatory sequences, including the promoters and UTRs,
have been shown to enhance translation and accumulation of
foreign proteins under continuous light (12). Therefore, the
pLD-VK1 transgenic lines were exposed to continuous light
and expression patterns were determined on days 1, 3, 5, and
7 (Fig. 2b). PA expression levels reached a maximum of 14.2%
of the TSP in mature leaves at the end of day 5 and the
expression levels declined to 11.7% TSP on day 7. The larger
amount of PA in mature leaves is probably due to the high
number of chloroplasts in mature leaves and the high copy
number of chloroplast genomes (up to 10,000 copies per cell).
The decrease in PA expression in bleached old leaves could be
due to degradation of the proteins during senescence. These
results show that approximately 1.8 mg PA can be obtained per
gram fresh weight of mature leaf upon exposure to 5-day con-
tinuous illumination. Thus, approximately 150 mg of PA can be
obtained from a single plant and with 8,000 tobacco plants on
an acre of land, 1.2 kg of PA can be obtained per single cutting
of tobacco plant (petit Havana variety, Table 1). Upon three
cuttings in a year, a total of 3.6 kg of PA can be obtained.
Assuming a loss of 50% during purification and 5 g PA per
dose (current vaccine dose is in a range of 1.75 to 7 g PA)
(17), a total of 360 million doses of vaccine can be obtained per
acre of land. The commercial cultivar yields 40 metric tons
biomass of fresh leaves as opposed to 2.2 tons in experimental
cultivar petit Havana (7). Therefore, the commercial cultivar is
expected to give 18-fold-higher yields than the experimental
cultivar. Thus an acre of land grown with transgenic tobacco
plants would yield vaccine sufficient for a very large population.
Functional analysis of PA with macrophage cytotoxicity as-
say. Figure 3a shows the Coomassie-stained gel of crude leaf
extracts and various purification fractions and the absence of
PA in the flowthrough. The expression level of PA is so high
that it can be observed in a Coomassie-stained gel even in
crude plant extracts. Figure 3b is a Coomassie-stained gel
showing fractions of purified and concentrated chloroplast-
derived PA used for immunization studies. Supernatant sam-
ples from crude extracts of plant leaves expressing PA and
partially purified chloroplast-derived PA were tested for func-
tionality in vitro using the well-defined macrophage lysis assay
(16). The transgenic plants were shown to produce fully func-
tional PA (Fig. 4). Crude extracts of wild-type tobacco plant
and plant extraction buffer were used as negative controls. The
crude extract of plant leaves expressing PA had activity equal
to that of a 20-g/ml solution of purified B. anthracis-derived
PA. These results show that the PA expressed in plants has
high functional activity.
FIG. 3. Purification of PA by affinity chromatography from the
crude extracts of plant leaves expressing PA. (a) Coomassie staining of
the proteins in crude extract and purified protein: Lane 1, protein plus
precision ladder; lane 2, wild-type leaf crude extract; lane 3, crude
extract of transgenic plant expressing PA; lanes 4 and 5, purified
chloroplast-derived PA; lane 6, flowthrough collected during purifica-
tion. (b) Lane 1, ladder; lane 3, concentrated protein; lane 5, purified
protein (before concentrating); lanes 2 and 4, overflow from lane 3.
TABLE 1. Yield of PA expressed in pLD-VK1 tobacco plant T0 transgenic line relative to its biomass
Leaf age No. of leaves/plant Average wt (g)/leaf Amt of PA (mg/g) in fresh leaf
Amt (mg) of PA % of PA in relation to
whole plantbPerleaf Per age groupa
Young 3.5 2.5 0.8 2 7.0 4.61
Mature 8.2 8.0 1.86 14.88 122.01 80.43
Old 4.5 5.6 0.9 5.04 22.68 14.95
a The total amount of rPA per plant per age group was 151.69 mg.
b The total percentage of rPA per plant in relation to the whole plant was 100%.
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Immunization of BALB/c mice. Having confirmed that the
chloroplast-derived PA has in vitro biological activity compa-
rable to that of the B. anthracis-derived PA, we proceeded
further to investigate the functionality in vivo. For this, seven
groups each consisting of five mice were injected s.c. with 5 g
of the antigen on days 0, 14, 28, and 140. The group 1 and
group 2 mice, immunized with chloroplast-derived partially
purified PA and with B. anthracis-derived fully purified PA,
respectively, both adsorbed to alhydrogel adjuvant, showed
comparable IgG immune titers of about 1:300,000 (Fig. 5a).
These observations are comparable to those of earlier studies
where anti-PA titers up to 1:250,000 were observed in guinea
pigs immunized with PA along with adjuvant (4). The obser-
vation that the chloroplast-derived PA and PA derived from B.
anthracis show comparable immune responses suggests that
the plant-derived PA has been properly folded and was fully
functional. The group that received partially purified chloro-
plast-derived PA without adjuvant showed titers ranging from
1:10,000 to 1:40,000, while the mice that received PA derived
from B. anthracis without adjuvant showed titers of 1:80,000 to
1:160,000. Previous studies showed that mice immunized s.c.
with recombinant PA (rPA) derived from B. anthracis along
with the adjuvant had significant antibody titers, while no sig-
nificant immune response was observed in the group immu-
nized with PA alone (13). Similarly, guinea pigs immunized s.c.
with rPA derived from B. subtilis did not elicit a significant IgG
immune response, while rPA with alhydrogel adjuvant showed
significant levels of IgG titers above 1:15,000 (20). Taken to-
gether, these studies show that PA alone may not be a potent
immunogen to elicit a significant immune response and there-
fore all currently used anthrax vaccines contain an adjuvant.
The difference between the immune responses between the
two groups immunized with chloroplast-derived PA and B.
anthracis-derived PA could be due to differences in the purities
of the proteins. The level of purity was extremely high in PA
derived from B. anthracis because of the use of anion-exchange
and gel filtration chromatography and fast protein liquid chro-
matography (FPLC) to eliminate the breakdown products of
the PA (21), whereas chloroplast-derived PA was purified by
affinity chromatography without using protease inhibitors. In
the presence of adjuvant, PA binds to the alhydrogel via elec-
trostatic forces (21), making it more stable against proteolytic
degradation. Differences in the titer values of the groups that
received PA with and without adjuvant were probably due to
depot effect (2) and due to the alhydrogel’s nonspecific priming
of the immune system. The group that received transgenic
plant crude extracts expressing PA with adjuvant showed IgG
titers ranging from 1:40,000 to 1:80,000. In spite of significant
levels of impurities in the crude extract, this group showed
good immune titers, confirming high expression levels of PA in
transgenic leaves.
Toxin neutralization assay of serum samples. In order to
evaluate the functionality of the IgG antibodies produced in
response to the immunization, sera from the mice were tested
for their ability to neutralize PA and thereby protect macro-
phages against LT killing. Toxin neutralization assays were
performed on two different sets of sera. The first set was drawn
15 days after the third immunization dose (day 43 of post-
initial immunization), and the second set was drawn 15 days
after the fourth immunization dose (day 155 of post-initial
immunization). Sera obtained after the third dose (Fig. 5b)
showed similar neutralization titers for the mice immunized
with chloroplast-derived PA or B. anthracis-derived PA when
both proteins were administered with adjuvant (1:10,000 to
1:100,000). These observations are in agreement with the re-
sults obtained in earlier studies where neutralization titers of
20,000 to 70,000 were obtained when guinea pigs were immu-
nized with PA derived from B. anthracis along with adjuvant
(4). However, titers were slightly higher for B. anthracis-de-
rived PA used in conjunction with adjuvant in bleeds after the
fourth immunization (Fig. 5c). The mice immunized with chlo-
roplast-derived PA alone showed significantly smaller neutral-
ization titers (between 1:100 and 1:1,000) than the mice im-
munized with B. anthracis-derived PA alone (1:10,000 to
FIG. 4. Functional analysis of PA with macrophage cytotoxicity assay. The cytotoxicities of various PA preparations for mouse macrophage
RAW264.7 cells were assayed in the presence of LF. Samples that were diluted serially were as follows: crude extract of plant leaves expressing
PA with His tag, wild-type (WT) plant leaf crude extract, 20-g/ml stock of purified chloroplast-derived PA, 20-g/ml stock of purified PA derived
from B. anthracis, and plant protein extraction buffer.
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1:200,000 after the third immunization and 1:10,000 to 1:50,000
after the fourth immunization, Fig. 5b and c). Mice immunized
with the crude extracts of PA-expressing leaves showed strong
neutralization titers, ranging from 1:500 to 1;7500, with the
exception of a single mouse after the fourth immunization
(Fig. 5c). Control mice immunized with wild-type plant leaf
crude extract or PBS did not show any immune response or
neutralization ability. Generally, the average neutralization ti-
ters compared among different groups showed similar distri-
bution patterns to that of the average anti-PA immune titers
determined by the ELISA. These results show that there is
good correlation between the anti-PA antibody levels and neu-
tralization titers.
Toxin challenge of BALB/c mice. We proceeded to test the
immunized mice for their ability to survive challenge with
1.5  100% lethal dose (LD100) of LT (22). Mice immunized
with the chloroplast or B. anthracis-derived PA with adjuvant
survived the toxin challenge. Mice immunized with crude ex-
tracts of plants expressing PA showed a significant survival rate
of 80%, confirming high PA expression levels. In this group, 4
out of 5 mice showed neutralization titers above 1:1,000. These
studies demonstrate the immunoprotective properties of chlo-
roplast-derived PA against anthrax LT challenge. The single
mouse in this group that showed a neutralization titer below
1:150 may have been the one to succumb. None of the mice
immunized with chloroplast-derived PA without adjuvant sur-
vived (Fig. 6), as expected from their low neutralization titers
(Fig. 5b and c). The comparison of neutralization titers to
mouse challenge survival for all the groups seems to indicate
neutralization titers at and above 1:1,000 result in protection
against challenge with greater than LD100 doses of LT.
These results prove the immunogenic and immunoprotec-
tive properties of plant-derived B. anthracis PA. Prior studies
did not investigate functionality of plant-derived PA in animal
studies (3, 30). The production of anti-PA IgG antibodies
combined with in vitro neutralization and toxin challenge stud-
ies shows that immunization with transgenic chloroplast-de-
rived PA is highly effective. Plant-derived recombinant PA is
free of EF and LF and easy to produce, without the need for
expensive fermenters. Even with 50% loss during purification,
1 acre of transgenic plants can produce 360 million doses of
functional anthrax vaccine. Our studies open the door for
possible oral immunization through feeding of edible plant
FIG. 5. IgG antibody titers and toxin neutralization assay titers in
serum samples obtained from mice after third and fourth doses. (a)
Comparison of immune responses in serum samples of mice adminis-
tered subcutaneously with chloroplast-derived PA (CpPA) with adju-
vant (column 1), chloroplast-derived PA (CpPA) alone (column 2),
Std-PA derived from B. anthracis with adjuvant (column 3), Std-PA
alone (column 4), PA plant leaf crude extract with adjuvant (column
5), wild-type plant leaf crude extract with adjuvant (column 6), and
unimmunized mice (column 7). (b) Toxin neutralization titers of sera
collected from the mice on day 43 of post-initial immunization. Each
symbol represents average EC50 from three replicate assays of a single
mouse serum. CHL, chloroplast; ADJ, adjuvant; B.A., B. anthracis;
WT, wild type. (c) Toxin neutralization assays of serum samples col-
lected from the mice on day 155 of post-initial immunization. Each
symbol represents the average EC50 from three replicate assays of a
single mouse serum.
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parts like carrot roots, which should effectively stimulate the
mucosal immune system as well as a systemic immune re-
sponse, thereby offering better protection against pathogens
that attack through mucosa. Delivering vaccines in edible
plants can potentially eliminate existing vaccine purification
and processing steps, cold storage and transportation require-
ments, and the need for health professionals for vaccine deliv-
ery. Although foreign genes have been expressed in chromo-
plasts of edible plant parts (18), there is no report of expressing
vaccine antigens in non-green plastids present within edible
tissues so far. In addition to maternal inheritance of transgenes
engineered via the chloroplast genomes (8), cytoplasmic male
sterility has been developed as another fail-safe mechanism for
biological containment of transgenes (27). Furthermore, suc-
cessful engineering of several foreign operons via the chloro-
plast genome (24) has opened the door for development of
multivalent vaccines.
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